"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving SolutionsSurge Driven by Ozempic and Zepbound Prescription ...

Economists around the world expect muted U.S. economic growth in the coming quarters, and some indicators have shown an increased likelihood of a 2025 recession in recent weeks. [ Sign up for ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its ...